System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 1 citation

PubMed: 39594763 DOI: 10.3390/cancers16223809

Diagnostic Utility of MicroRNAs in Pancreatic Cancers.

Cancers (Basel) 16(22)

Authors: Wojciech Jelski, Jan Mroczko, Sylwia Okrasinska, Barbara Mroczko

Affiliations

  • Department of Biochemical Diagnostics, Medical University, 15-276 Bialystok, Poland.
  • Department of Biochemical Diagnostics, University Hospital, 15-268 Bialystok, Poland.
  • Department of Neurodegeneration Diagnostics, Medical University, 15-268 Bialystok, Poland.

Abstract

Pancreatic cancer (PC) is a serious malignant tumor with a high mortality rate, mainly due to late diagnosis and a lack of effective therapeutic interventions. The possibility of recognizing this cancer with reliable biomarkers using minimally invasive methods is of great importance for improving early detection, prognostic assessment, and targeted treatment methods. In recent years, small non-coding RNAs, especially microRNAs, have emerged as promising candidates for biomarkers of pancreatic cancer. Despite the methodological and analytical limitations of microRNA determination and a lack of available automated and standardized tests, a prospective systematic assessment of this new parameter's use in the detection of pancreatic cancer is warranted. This review provides general information on the diagnostic and prognostic utility of microRNAs, which appear to be well-established in many studies. In summary, microRNAs are promising non-invasive biomarkers of pancreatic cancer, offering potential opportunities for early detection, prognosis, and treatment monitoring. As research in this field progresses, microRNAs should become valuable tools in the fight against pancreatic cancer.

MeSH

Pancreatic Neoplasms, Micrornas, Neoplasms, Biomarkers, Therapeutics

Cited by